CD33 and benign prostatic hyperplasia: Conversely, Chi et al., reported that circulating CD33+CD11b+HLA-DR−CD14− granulocytic MDSCs represented the major subtype of MDSCs in patients with prostate cancer and their level were significantly elevated compared with both healthy donors and patients with benign prostatic hyperplasia (BPH) (190).